AAO 2020 eBook – Dry Eye Featuring Impact of Dry Eye Signs & Symptoms on Work Productivity Severe DED in Chronic GVHD: Assessing the Role of Serum Vitamin A Examining the Role of Microneuromas Markers in Neuropathic...
HBM9036 ophthalmic solution 0.25%, also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...
Dry eye disease (DED) is a highly prevalent syndrome that manifests with symptoms that include constant irritation, burning or stinging sensations, and feelings of grittiness in the eyes. “DED is a chronic pain syndrome often...
HBM9036 ophthalmic solution 0.25%, also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...
New data from the phase 2 IMPERIAL clinical trial evaluating OC-01 (varenicline) nasal spray in the treatment of the signs and symptoms of dry eye disease in adults were presented at the AAO 2020 Virtual Annual Meeting. A single...
Contributing to this article, Shahzad I. Mian, MD, Professor, Ophthalmology and Visual Sciences, Vice Chair, Clinical Sciences and Learning, Kellogg Eye Center, Michigan Medicine Previous research has shown that patients...
When managing dry eye disease (DED), ensuring realistic patient expectations is critical to...
To optimize care for dry eye disease (DED), clinicians are recommended to take a stepwise approach...
